Blue Owl Capital Holdings LP Invests $1.52 Million in KalVista Pharmaceuticals, Inc. $KALV

Key Points

• Blue Owl Capital purchased a new stake of 125,000 shares in KalVista Pharmaceuticals in Q3, valued at about $1.52 million, representing roughly 0.25% ownership.
• Insiders have been net sellers recently—CEO Benjamin L. Palleiko sold 10,034 shares and another insider sold 5,354 on Feb 23; insiders have sold 33,979 shares worth about $535,091 in the last 90 days and currently own 4.3% of the stock.
• Analyst sentiment is broadly positive with a consensus rating of Moderate Buy (seven Buys, one Sell) and a consensus price target of $29.40.

Blue Owl Capital Holdings LP purchased a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 125,000 shares of the specialty pharmaceutical company's stock, valued at approximately $1,522,000. Blue Owl Capital Holdings LP owned about 0.25% of KalVista Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. BNP Paribas Financial Markets increased its holdings in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company's stock worth $46,000 after purchasing an additional 1,292 shares in the last quarter. Wolverine Asset Management LLC acquired a new stake in shares of KalVista Pharmaceuticals during the third quarter valued at about $57,000. KLP Kapitalforvaltning AS acquired a new stake in shares of KalVista Pharmaceuticals during the third quarter valued at about $63,000. Virtus Investment Advisers LLC bought a new stake in shares of KalVista Pharmaceuticals during the second quarter worth about $81,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of KalVista Pharmaceuticals by 816.8% during the second quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company's stock worth $91,000 after purchasing an additional 7,180 shares during the last quarter.

KalVista Pharmaceuticals Price Performance

Shares of KALV opened at $16.23 on Friday. KalVista Pharmaceuticals, Inc. has a 1 year low of $9.23 and a 1 year high of $19.00. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The company has a market capitalization of $820.43 million, a price-to-earnings ratio of -4.11 and a beta of -0.35. The business has a 50-day moving average of $15.57 and a 200-day moving average of $14.11.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on KALV shares. TD Cowen reiterated a "buy" rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Citigroup restated a "market outperform" rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Needham & Company LLC raised their price target on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a "buy" rating in a research note on Tuesday, January 6th. Finally, Citizens Jmp cut their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a "market outperform" rating on the stock in a report on Tuesday, November 11th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.40.

Insider Activity

In other news, CEO Benjamin L. Palleiko sold 10,034 shares of the company's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $156,229.38. Following the sale, the chief executive officer directly owned 442,883 shares of the company's stock, valued at approximately $6,895,688.31. This represents a 2.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Paul K. Audhya sold 5,354 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $83,361.78. Following the sale, the insider owned 138,983 shares of the company's stock, valued at approximately $2,163,965.31. This trade represents a 3.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,979 shares of company stock worth $535,091 in the last 90 days. 4.30% of the stock is owned by company insiders.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.